According to GlobalData’s medical device pipeline database, 53 Bioabsorbable Stents (BAS) devices are in various stages of development globally. GlobalData’s report Bioabsorbable Stents (BAS) provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 21 are in active development, while the remaining 33 are in an inactive stage of development. There are seven products in the early stages of development, and the remaining 14 are in the late stages of development.
Cardiovascular Devices are used to detect and treat heart and circulatory system related diseases. A bioabsorbable stent (also called bioresorbable scaffold, biodegradable stent or naturally-dissolving stent) is a stent that is made of a material that can be absorbed by the body. Bioabsorbable Coronary Stents are used to treat coronary artery disease, which is a narrowing of the arteries that supply blood to the heart. They are inserted into the narrowed artery and then expanded to open the artery and improve blood flow. These stents will eventually dissolve in the body and avoids second procedure to remove the stent.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Bioabsorbable Stents (BAS) pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Bioabsorbable Stents (BAS) devices. Overall, most of these Bioabsorbable Stents (BAS) pipeline devices are being developed by private entities.
Key players involved in the active development of Bioabsorbable Stents (BAS) include Amaranth Medical, MIV Therapeutics, Xenogenics, Shanghai Bio-heart Biological Technology, OrbusNeich, Meril Life Sciences, MicroPort Scientific, Biotronik, Biotronik SE and Biotyx Medical (Shenzhen).
For a complete picture of the developmental pipeline for Bioabsorbable Stents (BAS) devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
